Emerging research suggest Retatrutide , a dual agonist targeting both the gut-brain axis and glucose-dependent insulinotropic polypeptide , could represent a notable advancement for weight loss . Initial human tests have indicated substantial decreases in visceral mass , possibly outperforming current weight-loss therapies . Despite this, additiona